Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.030
+0.020 (1.98%)
At close: Aug 13, 2025, 4:00 PM
1.040
+0.010 (0.95%)
Pre-market: Aug 14, 2025, 8:03 AM EDT
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Lineage Cell Therapeutics stock ranges from a low of $2.00 to a high of $9.00. The average analyst price target of $4.20 forecasts a 307.77% increase in the stock price over the next year.
Price Target: $4.20 (+307.77%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Lineage Cell Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +94.17% | Aug 14, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +94.17% | Aug 5, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +94.17% | Jun 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +773.79% | Jun 23, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $4 → $3 | Strong Buy | Maintains | $4 → $3 | +191.26% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
6.83M
from 9.50M
Decreased by -28.08%
Revenue Next Year
23.57M
from 6.83M
Increased by 244.95%
EPS This Year
-0.09
from -0.09
EPS Next Year
-0.05
from -0.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10.1M | 39.4M | 78.6M |
| Avg | 6.8M | 23.6M | 18.7M |
| Low | 5.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 6.1% | 476.3% | 233.7% |
| Avg | -28.1% | 245.0% | -20.5% |
| Low | -45.2% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.01 | 0.03 | -0.05 |
| Avg | -0.09 | -0.05 | -0.09 |
| Low | -0.15 | -0.15 | -0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.